Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure
| Autor: | Eoin O'Connell, Elaine Tallon, Stephanie James, Joe Gallagher, John A. Baugh, Donal O'Shea, Kenneth McDonald, James O’Reilly, Chris J Watson, Jean O'Connell, Mark Ledwidge |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Health Toxicology and Mutagenesis Clinical Biochemistry 030204 cardiovascular system & hematology Biochemistry Asymptomatic Severity of Illness Index 03 medical and health sciences 0302 clinical medicine SDG 3 - Good Health and Well-being Risk Factors Diabetes mellitus Internal medicine Severity of illness Natriuretic Peptide Brain Natriuretic peptide medicine Humans Mass Screening 030212 general & internal medicine Mass screening Aged Heart Failure business.industry Case-control study Middle Aged medicine.disease Diabetes Mellitus Type 2 ROC Curve Heart failure Case-Control Studies Cardiology Population study Female medicine.symptom business Biomarkers |
| Zdroj: | Watson, C, James, S, O'Connell, E, Gallagher, J, O'Reilly, J, Tallon, E, Baugh, J, O'Connell, J, O'Shea, D, Ledwidge, M & McDonald, K 2016, ' Influence of diabetes on natriuretic peptide thresholds in screening for Stage B heart failure ', Biomarkers, vol. 21, no. 6, pp. 538-543 . https://doi.org/10.3109/1354750X.2016.1160427 |
| DOI: | 10.3109/1354750X.2016.1160427 |
| Popis: | Context: Natriuretic peptide (NP) has been shown to be an effective screening tool to identify patients with Stage B heart failure and to have clinical value in preventing heart failure progression. The impact of associated metabolic confounders on the screening utility of NP needs clarification.Objective: To assess the impact of diabetes mellitus (DM) on NP screening for asymptomatic Stage B heart failure.Materials and methods: The study population consisted of 1368 asymptomatic patients with cardiovascular risk factors recruited from general practice as part of the STOP-HF trial. B-type NP (BNP) was quantified at point-of-care.Results: BNP was found to be as accurate for detecting Stage B heart failure in DM patients compared to non-DM patients (AUC 0.75 [0.71,0.78] and 0.77 [0.72,0.82], respectively). However, different BNP thresholds are required to achieve the same level of diagnostic sensitivity in DM compared with non-DM patients. To achieve 80% sensitivity a difference of 5-ng/L lower is required for patients with DM.Conclusion: Although a significantly different BNP threshold is detected for patients with DM, the BNP concentration difference is small and unlikely to warrant a clinically different diagnostic threshold. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|